CoChat

A Two-Year Clinical Follow-Up Study in 80 CADASIL Subjects: Progression Patterns and Implications for Clinical Trials

Open access
Peters, Nils, Herzog, Jürgen, Opherk, Christian, Dichgans, Martin · 2004 · Stroke
Cited by 112

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

Background and Purpose— Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is an inherited small vessel disease causing stroke and dementia. The aim of this study was to explore the patterns of clinical progression in CADASIL, to check for prognostic variables, and to provide sample size estimates for future therapeutic trials. Methods— Eighty CADASIL subjects (aged 45.7±9.9 years [mean+SD]) were followed prospectively during a mean period of 26.3±1.1 months. Standardized scales on disability (Rankin), activities of daily living (Barthel index), neurological outcome (National Institutes of Health Stroke Scale [NIHSS]), and cognition (structural interview for diagnosis of Alzheimer dementia and multi-infarct dementia [SIDAM] and Mattis dementia rating scale [MDRS]) were assessed at baseline and at follow-up. Results— All but 1 individual completed the protocol. At follow-up, the cohort had deteriorated with respect to all clinical scales: Rankin scores (0.3±0.7 [mean change±SD]; P =0.001), Barthel index (−5.4±15.9; P <0.001), NIHSS scores (1.0±2.6; P =0.001), SIDAM scores (−2.1±6.4; P =0.004), and MDRS scores (−4.3+18.5; P =0.09). The spectrum ranged from marked worsening to some degree of improvement. Seventeen patients experienced a new stroke. Overall, there were 18 strokes within 173 person-years, giving an average incidence rate of stroke of 10.4 per 100 person-years (95% CI, 5.6 to 15.2). Age at baseline was found to be a predictor of clinical progression. Sample size estimates show that the number of individuals needed to include in an interventional trial (assumed duration 2 years, assumed treatment effect 40%) is 602 when using stroke occurrence as an outcome measure. Conclusions— The clinical course of CADASIL includes periods of acute worsening, chronic progression, stabilization, and improvement. Sample size calculations emphasize the need for surrogate markers of disease progression for future interventional trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/01.str.0000131546.71733.f1

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

See all 112

Metadata

Authors
Peters, N., Herzog, J., Opherk, C., & Dichgans, M.
Venue
Stroke
Published
2004-07
Volume
35
Issue
7
Pages
1603-1608
ISSN
  • 0039-2499 (ISSN-L)
  • 1524-4628
OpenAlex
W2125281913
Cited by
112
References
12
FWCI
4.01
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Two-Year Clinical Follow-Up Study in 80 CADASIL Subjects: Progression Patterns and Implications for Clinical Trials. https://app.cochat.ai/papers/10.1161/01.str.0000131546.71733.f1
The paper
Peters, N., Herzog, J., Opherk, C., & Dichgans, M. (2004). A Two-Year Clinical Follow-Up Study in 80 CADASIL Subjects: Progression Patterns and Implications for Clinical Trials. Stroke. https://doi.org/10.1161/01.str.0000131546.71733.f1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.